DuplexSeq for MRD in AML

About TwinStrand Biosciences

TwinStrand Biosciences has pioneered Duplex Sequencing®, a proprietary error-corrected NGS technology that achieves an error rate of less than 1 in 10 million, representing a >10,000-fold improvement over standard NGS. This ultra-sensitive platform is being applied to key areas including measurable residual disease (MRD) monitoring in hematological cancers like AML and next-generation genetic toxicology assays for regulatory safety assessment. The company is transitioning its mutagenesis assay business through an acquisition by Scantox while focusing on advancing its diagnostic and research applications, positioning itself at the forefront of high-fidelity genomic analysis.

Therapeutic Areas